<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03219632</url>
  </required_header>
  <id_info>
    <org_study_id>ACADEMY</org_study_id>
    <nct_id>NCT03219632</nct_id>
  </id_info>
  <brief_title>Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG</brief_title>
  <official_title>Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the efficacy of fimasartan on left ventricular hypertrophy in hypertensive patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who were diagnosed with left ventricular hypertrophy (LVH) by ECG at the start of
      the study are followed up at 3-month intervals for 1 year.

      Increase Fimasartan if blood pressure is not controlled.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 5, 2012</start_date>
  <completion_date type="Actual">May 30, 2017</completion_date>
  <primary_completion_date type="Actual">April 30, 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>The change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG (composite).</measure>
    <time_frame>1 year</time_frame>
    <description>Measurements of changes in baseline at 12 months (change in systolic and diastolic blood pressure, left ventricular hypertrophy in ECG)</description>
  </primary_outcome>
  <enrollment type="Actual">72</enrollment>
  <condition>Left Ventricular Hypertrophy</condition>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <description>Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Registered 319 people considering 30% dropout rate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have been treated or not treated with hypertension from 20 to 80 years of
             age

          -  Patients with electrocardiographic left ventricular hypertrophy (In this study, we
             define left ventricular hypertrophy if one of the following two criteria is met)

               1. RaVL+SV3 &gt; 20mm(M). 16mm(F)

               2. SV1+RV5 or RV6 &gt; 35mm.

          -  Patients who are taking or expecting Fimasartan

        Exclusion Criteria:

          -  Patients with unstable angina or myocardial infarction within 3 months

          -  Patients with clinically significant severe valve disease, congenital heart disease,
             peripheral vascular disease, cerebrovascular disease

          -  Clinically significant severe congestive heart failure patients

          -  Patients with renal dialysis

          -  Clinically significant renal disease patients

          -  Patients with clinically significant hepatic impairment

          -  Patients with a history of alcohol or substance abuse

          -  Patients with hypersensitivity to angiotensin-receptor blocker

          -  Patients needing angiotensin-receptor blocker drugs other than fimasartan

          -  For women, pregnancy, Patients who are breastfeeding or planning to become pregnant

          -  A person who is determined to be inappropriate by the Investigator

          -  Patients participating in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Ju choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001 Mar;141(3):334-41.</citation>
    <PMID>11231428</PMID>
  </reference>
  <reference>
    <citation>Katholi RE, Couri DM. Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens. 2011;2011:495349. doi: 10.4061/2011/495349. Epub 2011 Jun 30.</citation>
    <PMID>21755036</PMID>
  </reference>
  <reference>
    <citation>Sadoshima J, Izumo S. Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993 Sep;73(3):413-23.</citation>
    <PMID>8348686</PMID>
  </reference>
  <reference>
    <citation>Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B; Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation. 2003 Aug 12;108(6):684-90. Epub 2003 Jul 28.</citation>
    <PMID>12885747</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2017</study_first_posted>
  <last_update_submitted>July 14, 2017</last_update_submitted>
  <last_update_submitted_qc>July 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

